With its AI-enabled in vivo cell reprogramming (in situ transdifferentiation) technology platform, Neuregen is capable of developing FIC therapeutic products for cancers, regenerative medicine and anti-aging.

And it is actively exploring financing and strategic partnering opportunities with established pharmas and health product companies globally:

Licensing out/Co-development、Strategic Partnership、Equity Investment、NewCo/Joint Venture、M&A